Archivo de la etiqueta: DEA

Pharmas are increasingly outsourcing R&D to CROs to expedite drug development and reduce costs. The model is working well so far, as the fast production of the Covid-19 vaccine showed. CROs perform their tasks efficiently and are growing in number, size and scope. There are, however, important risks in this strategy which should be considered. Understanding this unique model is enriching not only for the pharma industry but also for those interested in the generation of new knowledge and in outsourcing. Sigue leyendo →